Diaminopyrimidinecarboxamide derivative

Abstract

A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

1 . A STAT 6 activation inhibitor which comprises a diaminopyrimidinecarboxamide derivative represented by a formula (I) or a salt thereof and a pharmaceutically acceptable carrier, 
       
         
           
           
               
               
           
         
         (symbols in the formula have the following meanings: 
         A 1 : CR 5  or N,
 R 5 : —H, -lower alkyl, —O-lower alkyl or -halogen, 
 
         A 2 : CR 6  or N,
 R 6 : —H or -halogen, 
 
         R 3 : —R 0 , -lower alkyl substituted with halogen, -halogen, —OR 0 , —S-lower alkyl, —CO-lower alkyl, —CO 2 -lower alkyl, -lower alkylene-OH, -hetero ring, —O-hetero ring, —N(R 0 )-hetero ring, -lower alkylene-hetero ring, —O-lower alkylene-hetero ring, —S-lower alkylene-hetero ring, —SO-lower alkylene-hetero ring, —SO 2 -lower alkylene-hetero ring, —N(R 0 )-lower alkylene-hetero ring, -lower alkylene-CO-hetero ring, -lower alkylene-N(R 0 ) 2 , —SO 2 —N(R 0 )-lower alkyl or -lower alkylene-N(R 0 )—CO 2 -lower alkylene-phenyl,
 R 0 : the same or different from one another, and each is H or a lower alkyl, 
 
         n: 0 or 2, 
         R 4 : (i) when n=2, —R 0 , lower alkyl substituted with halogen, —OR 0 , —N(R 0 )—CHO, —N(R 0 )—CO-lower alkyl or —N(R 0 )—SO 2 -lower alkyl,
 (ii) when n=0, —H, lower alkyl substituted with halogen, —OH, —NH—CHO, —CON(R 0 ) 2 , -lower alkylene substituted with halogen-OH, -lower alkylene-NH 2 , -lower alkylene-NHCONH 2 , -lower alkylene-CO 2 H, -lower alkylene-CO 2 -lower alkyl, -lower alkylene-CN, or —CH(lower alkylene-OH) 2 , or a group represented by a formula —X a —R 4a , 
 X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene-O—, -lower alkylene-N(R 0 )-, -lower alkylene-N(R 0 )CO—, -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 —, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, 
 k and m, the same or different from each other, and each is 0, 1, 2, 3 or 4, 
 R 4a : lower alkyl, phenyl, hetero ring, cycloalkyl, lower alkylene-phenyl, lower alkylene-hetero ring, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-hetero ring, 
 wherein the hetero rings in R 3  and R 4a  may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO, —SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , —CO—N(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0  or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , and 
 
         wherein the lower alkylene in R 3 , R 4 , R 4a  and X a  may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0  or hetero ring, or 
         R 3  and R 4  may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, *—N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—(CH 2 )—O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—,
 wherein * indicates bonding to the position shown by R 3 , 
 R 7 : —H, -lower alkyl or —CO-lower alkyl, 
 
         B: H, lower alkenyl, lower alkynyl, lower alkyl substituted with halogen, CN, S-lower alkyl, aryl which may have a substituent(s), cycloalkyl which may have a substituent(s) or hetero ring which may have a substituent(s), 
         Y: single bond; or lower alkylene which may be substituted with 1 to 5 groups selected from halogen, OH, O-lower alkyl, —NH 2 , —NH-lower alkyl and —N(lower alkyl) 2 , and R 1  and R 2 : the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)). 
       
     
     
         2 . The STAT 6 activation inhibitor described in  claim 1 , which is a Th2 cell differentiation inhibitor. 
     
     
         3 . A diaminopyrimidinecarboxamide derivative represented by a formula (Ia) or a salt thereof, 
       
         
           
           
               
               
           
         
         (symbols in the formula have the following meanings: 
         A 1 : CR 5  or N,
 R 5 : —H, -lower alkyl, —O-lower alkyl or -halogen, 
 
         R 3 : —R 0 , -lower alkyl substituted with halogen, -halogen, —OR 0 , —S-lower alkyl, —CO-lower alkyl, —CO 2 -lower alkyl, -lower alkylene-OH, -saturated hetero ring, —X b -heteroaryl, —X b -saturated hetero ring, —X b -heteroaryl, -lower alkylene-N(R 0 ) 2 , —SO 2 —N(R 0 )-lower alkyl or -lower alkylene-N(R 0 )—CO 2 -lower alkylene-phenyl,
 X b : -lower alkylene-, —O-lower alkylene-, —S-lower alkylene-, —SO-lower alkylene-, —SO 2 -lower alkylene-, —N(R 0 )-lower alkylene- or -lower alkylene-CO—, 
 R 0 : the same or different from one another, and each represents H or a lower alkyl, 
 
         R 4 : —X a -saturated hetero ring, -lower alkylene-saturated hetero ring or -lower alkenylene-saturated hetero ring,
 X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene-O—, -lower alkylene-N(R 0 )—, -lower alkylene-N(R 0 )CO— or -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 )—, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m , —CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, 
 k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4, 
 wherein the saturated hetero rings in R 3  and R 4a  may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO, —SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, saturated hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), heteroaryl, -lower alkylene-NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , —CO—N(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0  or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , and 
 
         wherein the lower alkylene in R 3 , R 4  and X a  may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0  or hetero ring, or 
         R 3  and R 4  may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, 
         *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, —N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—CH 2 —O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—, wherein * indicates bonding to the position shown by R 3 ,
 R 7 : —H, -lower alkyl or —CO-lower alkyl, 
 
         B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and 
         R 1  and R 2 : the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)). 
       
     
     
         4 . A diaminopyrimidinecarboxamide derivative represented by a formula (Ib) or a salt thereof, 
       
         
           
           
               
               
           
         
         (symbols in the formula have the following meanings: 
         A 1 : CR 5  or N,
 R 5 : —H; -lower alkyl, —O-lower alkyl or -halogen, 
 
         R 3 : -saturated hetero ring or —X b -saturated hetero ring,
 X b : -lower alkylene-, —O—, —N(R 0 )—, —O-lower alkylene-, —S-lower alkylene-, —SO-lower alkylene-, —SO 2 -lower alkylene-, —N(R 0 )-lower alkylene- or -lower alkylene-CO—, 
 R 0 : the same or different from one another, and each represents H or a lower alkyl, 
 
         R 4 : —H, -lower alkyl substituted with halogen, —OH, —NH—CHO, —CON(R 0 ) 2 , -lower alkylene substituted with halogen-OH, -lower alkylene-NH 2 , -lower alkylene-NHCONH 2 , -lower alkylene-CO 2 H, -lower alkylene-CO 2 -lower alkyl, -lower alkylene-CN, —CH(lower alkylene-OH) 2  or —X a —R 4a ,
 X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene-O—, -lower alkylene-N(R 0 )—, -lower-alkylene-N(R 0 )CO— or -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 )—, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO)—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, 
 k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4, 
 R 4a : lower alkyl, phenyl, heteroaryl, cycloalkyl, lower alkylene-phenyl, lower alkylene-heteroaryl, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-heteroaryl, 
 wherein the saturated hetero ring and heteroaryl in R 3  and R 4a  may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO, —SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , —CO—N—(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0  or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , or 
 
         the lower alkylene in R 3 , R 4 , R 4a  and X a  may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0  or hetero ring, or 
         R 3  and R 4  may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, 
         *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, *—N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—CH 2 —O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—, wherein * indicates bonding to the position shown by R 3 ,
 R 7 : —H, -lower alkyl or —CO-lower alkyl, 
 
         B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and 
         R 1  and R 2  the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent (s)). 
       
     
     
         5 . A diaminopyrimidinecarboxamide derivative represented by a formula (Ic) or a salt thereof, 
       
         
           
           
               
               
           
         
         (symbols in the formula have the following meanings: 
         R 5 : —H or -halogen, 
         B: phenyl which may have 1 to 3 substituents selected from lower alkyl and halogen, 
         Y: single bond or —CH 2 —, and 
         R 1  and R 2 : the same or different from each other, and each represents H or lower alkyl which may have a substituent(s)). 
       
     
     
         6 . A diaminopyrimidinecarboxamide selected from the group consisting of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 4-[(2,6-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2,6-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-fluoro-6-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-({4-[(1-methylpiperidin-3-yl)oxy]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-({4-[4-(2-amino-2-oxoethyl)piperazin-1-yl]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(2-morpholin-4-ylethoxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(β- D -glucopyranosyloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3-chloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2-thienylmethyl)amino]pyrimidine-5-carboxamide, 4-{[(3-chloro-2-thienyl)methyl]amino}-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide and 2-{[3-(2-morpholin-4-ylethyl)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide or salts thereof. 
     
     
         7 . A pharmaceutical composition which comprises the diaminopyrimidinecarboxamide derivative or a salt thereof described in  claims 3  to  6  and a pharmaceutically acceptable carrier. 
     
     
         8 . The composition described in  claim 7 , which is a preventive or therapeutic agent for respiratory diseases. 
     
     
         9 . The composition described in  claim 8 , which is a preventive or therapeutic agent for asthma. 
     
     
         10 . The composition described in  claim 8 , which is a preventive or therapeutic agent for a chronic obstructive pulmonary disease. 
     
     
         11 . Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in  claim 1 , or a salt thereof, for the manufacture of an STAT 6 activation inhibitor. 
     
     
         12 . Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in  claim 1 , or a salt thereof, for the manufacture of a Th2 cell differentiation inhibitor. 
     
     
         13 . A method for inhibitory activity for STAT 6 activation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in  claim 1 , or a salt thereof, to a mammal. 
     
     
         14 . A method for inhibitory activity for Th2 cell differentiation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in  claim 1 , or a salt thereof, to a mammal.